Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EDS01 and Toripalimab in Recurrent or Metastatic Head and Neck Tumors
NCT07625423Phase 1Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Mar 2026
- Primary completion
- Mar 2028
- Countries
- 1
01
Overview
Phase 1, open-label trial of Recombinant human endostatin adenovirus in head and neck cancer (HNC) and nasopharyngeal carcinoma (NPC) (3 arms), sponsored by West China Hospital of Sichuan University. Primary endpoint: Incidence of adverse events (AEs) and serious adverse events (SAEs) at 16 weeks. Started Mar 2026; status: recruiting.
02
Drugs
Recombinant human endostatin adenovirus
03
Conditions
head and neck cancer (HNC)nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT07625423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07625423.